Day: May 20, 2023

Figure 2 REDWOOD-HCM Cohort 4: Angina SymptomsFigure 1 REDWOOD-HCM Cohort 4: Kansas City Cardiomyopathy Questionnaire (KCCQ)Figure 4 REDWOOD-HCM Cohort 4: Cardiac BiomarkersFigure 3 REDWOOD-HCM Cohort 4: New York Heart Association (NYHA) Functional ClassTreatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical Trial in Non-Obstructive HCM To Begin in 2H 2023 SOUTH SAN FRANCISCO, May 20, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), a Phase 2, open-label clinical trial of aficamten in patients with non-obstructive...

Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced multiple presentations highlighting the broad application of its Gene Circuit technologies in multiple modalities at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Los Angeles, CA. “Our Gene Circuits are poised to potentially disrupt high-priority, unmet need diseases with smarter cell and gene therapies that can confer better activity, precision, and control,” said Timothy Lu, M.D., Ph.D., Chief Executive Officer...

AUSTIN, Texas, May 19, 2023 (GLOBE NEWSWIRE) — Volcon Inc. (NASDAQ: VLCN), (“Volcon” or the “Company”), the first all-electric, off-road powersports company, today announced that it intends to offer its securities in a firm commitment underwritten public offering (the “Offering”). The Company intends to use the net proceeds from the Offering for general corporate purposes, including working capital, operating expenses and capital expenditures. The offering is expected to close on May 24, 2023, subject to customary conditions. Aegis Capital Corp. is acting as the sole book-running manager for the Offering. The Company signed a securities purchase and exchange agreement (the “Agreement”) on May 19, 2023 to (1) issue an investor approximately $5 million original principal amount of nine (9) month convertible senior notes (the “New...

JACKSONVILLE, Fla., May 19, 2023 (GLOBE NEWSWIRE) — CSX Corp. (NASDAQ: CSX) has been recognized by intermodal providers as the top-performing railroad in North America. The “Intermodal Service Scorecard” ranking was compiled by the Journal of Commerce, and assessed performance through the first four months of 2023. To create the Scorecard, more than 100 shippers and intermodal marketing companies were invited to perform a satisfaction assessment. Respondents cited their satisfaction with domestic intermodal service as a key driver of CSX’s number one ranking. Customers highlighted improvements in the railroad’s fluidity, train speed and customer service. “CSX is proud to be recognized by our customers for the quality of our service delivery,” said President and CEO Joe Hinrichs. “CSX’s service performance has returned to — or in...

12 of 16 voting-eligible advisors vote “no” (with two abstentions) on question, “given the available efficacy and safety data, do the benefits of OCA 25 mg outweigh the risks in NASH patients with stage 2 or 3 fibrosis?” 15 of 16 voting-eligible advisors vote to “defer approval until clinical outcome data from trial 747-303 are submitted and reviewed, at which time the traditional approval pathway could be considered” PDUFA Target Action Date set for June 22, 2023 Company to host conference call on Monday, May 22, 2023, at 8:30 a.m. ET MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the outcome of the U.S. Food and Drug...

VANCOUVER, British Columbia, May 19, 2023 (GLOBE NEWSWIRE) — VERSES AI Inc. (NEO:VERS) (“VERSES” or the “Company”), a cognitive computing company specializing in next generation Artificial Intelligence, announces its plan to amend certain terms of an aggregate of 1,316,787 Class A subordinate voting share purchase warrants, which were issued as consideration to certain arm’s length finders (the “Finder Warrants”) as consideration for the introduction of certain subscribers to the Company in connection with its private placement offering of 20,000,000 special warrants (“Special Warrants”) at an issue price of $0.80 per Special Warrant for aggregate gross proceeds of $16,000,000, which completed in two tranches on October 21, 2021 and November 2, 2021. Each Finder Warrant is exercisable at an issue price of $0.80...